Healthy
Conditions
Keywords
Vaccinated, Negative SARS-CoV2 Test Result
Brief summary
The primary objective of the study is to evaluate the safety and tolerability of REGN15160 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). The secondary objectives of the study are: * To assess the concentration-time profile of REGN15160 in serum * To assess the immunogenicity of REGN15160
Interventions
DRUGREGN15160 (IV)
Administered in single intravenous (IV) dose
Administered in single IV dose
DRUGREGN15160 (SC)
Administered in single subcutaneous (SC) dose
Administered in single SC dose
Sponsors
Regeneron Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: 1. Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization using a local reverse transcription polymerase chain reaction (RT-PCR) test or other molecular diagnostic assay and sample collection following assay standards 2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening 3. Has a body mass index (BMI) between 18 and 31 kg/m2 (inclusive) at the screening visit 4. Is judged by the investigator to be in good health based on medical history, as defined in the protocol 5. Is in good health based on laboratory safety testing obtained at the screening visit Key
Exclusion criteria
1. History of clinically significant disease and any concern, as defined in the protocol and as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation 2. Was hospitalized (ie, \>24 hours) for any reason within 30 days of the screening visit 3. Has history of alcohol or drug abuse as determined by the investigator 4. Has a history of significant multiple and/or severe allergies (eg, latex gloves), or has had an anaphylactic reaction to prescription or non-prescription drugs or food 5. Use of any prescription and non-prescription medications or nutritional supplements within approximately 5 half-lives or 2 weeks, whichever is longer, prior to first administration of the study drug through the end of the study, except for the permitted medications listed 6. Participated in any clinical research study evaluating another investigational drug including biologics or therapy, including specific immunotherapy, within at least 5 half-lives or 90 days (whichever is longer) of an investigational biologic drug, or at least 4 weeks for small molecules or other investigational drugs, prior to the screening visit 7. Is a pregnant or breastfeeding woman 8. Is a woman of childbearing potential (WOCBP)1 who is unwilling to practice highly effective contraception (as defined in the protocol) prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after study drug administration NOTE: Other Protocol Defined Inclusion /
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence and severity of all treatment emergent adverse events (TEAEs) | Through Day 169 |
| Occurrence and severity of all serious adverse events (SAEs) | Through Day 169 |
Secondary
| Measure | Time frame |
|---|---|
| Concentrations of REGN15160 in serum | Through Day 169 |
| Incidence and titer of anti-drug antibodies (ADA) to REGN15160 | Through Day 169 |
Countries
Belgium
Outcome results
None listed